A Big Hit But A Small Miss? Ranbaxy’s Caduet Prospects In Doubt As Mylan Storms The Market
Executive Summary
A rollercoaster of a week for India’s Ranbaxy ends with yet another mystery – what is the status of its first-to-file applications for Pfizer’s Caduet?